サンプル依頼リスト カート
  • English
  • Korean
表紙：局所進行膵がんの世界市場-2023年～2030年
市場調査レポート
商品コード
1345400

局所進行膵がんの世界市場-2023年～2030年

Global Locally Advanced Pancreatic Cancer Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
局所進行膵がんの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の局所進行膵がん市場は、2022年に9億米ドルに達し、2023-2030年の予測期間中にCAGR 11.1％で成長し、2030年には20億米ドルに達すると予測されています。

膵がんは一般に、その攻撃的な腫瘍拡大と悲惨な予後によって代表されます。患者が膵がんを発症した場合、切除で治療できる可能性のある腫瘍は10％未満で、およそ3分の1が転移性です。残りの患者（膵がん患者の2分の1以上）は、隣接構造物への局所浸潤の結果として、局所進行性切除不能膵がん（LAPC）と考えられる状態にあります。

膵臓腺がんは最も侵攻性の高い腫瘍治療の一つであり、2030年までに欧米でがん関連死亡原因の第2位に浮上すると予想されています。この予測は過去20年間ほとんど増加しておらず、一般的な5年生存率は約8％です。膵がんは一般的に後期に診断され、意図しない体重減少、継続的な空腹感の喪失などが患者に見られるいくつかの症状です。局所進行膵がんの治療には、手術、放射線療法、化学療法、標的療法、免疫療法などがあり、病態に応じて選択されます。

膵がんの症例の増加、認識を広めるためのイニシアチブの増加、および他の要因の中の支援活動は、予測期間中に局所進行膵がんの世界市場の成長を後押しすると予想されます。さらに、資金調達と投資の増加に起因する研究活動の増加は、予測期間中の局所進行膵がんの世界市場の成長を後押しすると予想されます。

ダイナミクス

局所進行膵がんの症例増加が市場成長を牽引

局所進行膵がんの症例が世界的に増加していることが、予測期間中の世界市場の成長を後押しすると予想されます。例えば、膵がん患者の約30％が局所進行状態です。また、NCBIが発表した論文によると、ドイツでは2021年に約21,859人の膵がん患者が新たに登録されました。ニコチン喫煙の増加やタバコの消費量の増加が、このがんの患者数を増加させている要因のひとつです。

さらに、Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment（膵管腺がんの診断と治療の進歩）の論文で行われた予測によると、膵がんの患者数は増加すると予想されています。2025年までに新たな患者数は9829人、2040年までに37,824人増加すると評価されています。膵がんが原因の死亡率は、2025年には141,653人、2040年には169,389人と、2020年に比べて37,255人増加すると予測されています。繰り返しになるが、WCRFインターナショナルによれば、膵がんは世界で12番目に典型的ながんです。男性では12番目、女性では11番目のがんです。2020年には495,000人以上の膵がん患者が新たに発生すると予測されています。

増加する研究開発

膵がん治療のための研究開発の増加は、予測期間において世界の局所進行膵がん市場の成長を後押しすると予想されます。例えば、2022年1月、マルチターゲットT細胞療法は、米国食品医薬品局（FDA）により、膵がん治療のためのオーファンドラッグ（希少疾病用医薬品）に認定されました。この治療法は、化学療法と併用することで、進行性または転移性の膵がん患者において長期にわたる効果が期待できます。

さらに2022年1月、ノバルティスAGはNIS793の希少疾病用医薬品指定（ODD）を米国FDAから取得しました。NIS793は、膵がんおよびその他の腫瘍の治療において、追加の化学療法薬と統合されます。同様に、2023年6月、標的ブレンド療法をデザインする臨床段階のバイオ医薬品企業であるRenovoRx, Inc.は、局所進行膵がん（LAPC）を対象としたRenovoGem（ゲムシタビンの動脈内投与）の主要な第III相非盲検TIGeR-PaC試験から、無増悪生存期間（PFS）に関する新たな良好なデータを発表しました。

高額な治療費

膵がん治療にかかる高額な費用は、予測期間における局所進行膵がん世界市場の成長を妨げると推定されます。例えば、米国臨床腫瘍学会によると、6カ月コースの化学療法（ゲムシタビン）には約23,500米ドルが費やされます。エルロチニブという薬剤を併用すると、治療費は約40,000米ドルになります。

膵がん治療は高額治療であり、医療保険が適用されない個人の場合、膵がん治療には、治療の種類とスパンに基づいて、一般的に約50,000～200,000米ドル以上の費用がかかります。膵がん治療のエピソード総費用は35,601米ドル（FOLFOX）から45,851米ドル（リポソームイリノテカン）でしたが、その費用はレジメンによって異なります。同様に、NIHによると、膵臓切除とそれに対応する入院の未調整中間費用は約20,352米ドルでした。

治療の副作用

化学療法の副作用は、どの薬を投与するかによって異なります。また、同じ薬が投与されたとしても、すべての人に同じ副作用が起こるわけではないです。全体的な副作用としては、空腹感の低下、吐き気、嘔吐、下痢、胃腸障害、じんましん、口内炎、脱毛、エネルギー不足などがあります。化学療法を受けている患者はさらに、白血球、赤血球、血小板のレベルが低くなりやすく、貧血、感染症、あざ、出血の危険性が高まります。

膵がんに使用される薬剤の中には、典型的な副作用を伴うものもあります。例えば、カペシタビンは手のひらや足の裏に発赤や不快感を引き起こすことがあります。この状態は手足症候群と呼ばれます。オキサリプラチンは、末梢神経障害と呼ばれる手足の指の冷感しびれやしびれを誘発することがあります。末梢神経障害はナブパクリタキセルの副作用でもあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 局所進行膵がんの症例増加
      • 研究開発の増加
    • 抑制要因
      • 多額の治療費
      • 治療の副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • パイプライン分析
  • 規制分析
  • 特許分析
  • エンドユーザー動向
  • SWOT分析
  • DMIの見解
  • ロシア・ウクライナ戦争の影響

第6章 COVID-19分析

第7章 治療法別

  • 化学療法
    • ゲムシタビン
    • 5-フルオロウラシル（5-FU）
    • オキサリプラチン
    • アルブミン結合パクリタキセル（アブラキサン）
    • カペシタビン（経口5-FU製剤）
    • シスプラチン
    • イリノテカン
    • その他
  • 免疫療法
    • ドスターリマブ
    • ペムブロリズマブ
  • 標的療法
    • ラロトレクチニブ
    • エントレクチニブ
  • 放射線療法
  • 手術療法
    • 膵頭十二指腸切除術
    • 膵全摘術
    • 膵尾部切除術

第8章 投与経路別

  • 経口
  • 注入
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 研究機関
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • GSK
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Getwell
  • Ipsen Biopharmaceuticals, Inc.
  • Novartis Pharmaceuticals Corporation
  • Pfizer
  • Bayer HealthCare Pharmaceuticals, Inc.
  • Genentech USA, Inc.
  • AstraZeneca

第13章 付録

目次
Product Code: PH6764

Overview

Global Locally Advanced Pancreatic Cancer market reached US$ 0.9 billion in 2022 and is expected to reach US$ 2.0 billion by 2030, growing with a CAGR of 11.1% during the forecast period 2023-2030.

Pancreatic cancer is generally represented by its aggressive tumor expansion and dismal prognosis. When patients demonstrate pancreatic cancer, less than 10% have tumors that are potentially treatable with resection, and roughly one-third have metastatic conditions. The rest (more than one-half of all patients with pancreatic cancer) have a condition that is believed to be locally progressive and unresectable pancreatic cancer (LAPC) as an outcome of local invasion of adjacent structures.

Pancreatic adenocarcinoma is among the most aggressive therapy of tumor and is expected to emerge as the second top reason for cancer-related mortalities in Europe and the United States by 2030. The projection has barely enhanced over the last twenty years and stays down, with a general 5-year survival rate of roughly 8% individuals affected with the condition. Pancreatic cancer is generally diagnosed in later stages, and unintended weight loss, continued loss of hunger, etc. are a few manifestations noticed in patients. The treatment for locally advanced pancreatic cancer includes surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy selected depending on the condition.

The growing cases of pancreatic cancer, increasing initiatives to spread awareness, and support efforts among other factors are expected to boost the global locally advanced pancreatic cancer market growth during the forecast period. Further, the increasing research activities owing to the rising fundings and investments are expected to boost the global Locally Advanced Pancreatic Cancer market growth in the forecast period.

Dynamics

Growing Cases of Locally Advanced Pancreatic Cancer Drive the Market Growth

The growing cases of locally advanced pancreatic cancer globally are expected to boost the global market growth during the forecast period. For instance, approximately 30% of individuals with pancreatic cancer are with locally advanced conditions. Also, according to an article published by NCBI, about 21,859 new patients of pancreatic cancer were registered in Germany in 2021. The growth in nicotine smoking and the increase in tobacco consumption are among the factors leading to the boost in the number of patients with this cancer.

Moreover, according to the forecasts made in Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment article, the number of individuals with pancreatic cancer is expected to grow. By 2025, it is assessed that the number of fresh cases will grow by 9829, and by 2040 by 37,824. The pancreatic cancer-caused mortality is expected to rise to 141,653 deaths in 2025, and to 169,389 in 2040 around 37,255 more deaths compared to 2020. Again, according to WCRF International, pancreatic cancer is the 12th most typical cancer globally. It is the 12th most typical cancer in males and the 11th most expected cancer in females. There were over 495,000 fresh cases of pancreatic cancer in 2020.

Increasing Research Developments

The increasing research development for the treatment for pancreatic cancer treatment are expected to boost the global locally advanced pancreatic cancer market growth in the forecast period. For instance, The January 2022, Multitargeted T-cell therapy was awarded orphan drug status by the U.S. Food and Drug Administration (FDA) for the therapy of pancreatic cancer. When utilized in combination with chemotherapy, this therapy has the prospect of producing long-lasting results in individuals with progressive or metastatic pancreatic cancer.

Further, in January 2022, Novartis AG obtained an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It integrates with additional chemotherapy medicines for the treatment of pancreatic cancer and other tumors. Similarly, in June 2023, RenovoRx, Inc., a clinical-stage biopharmaceutical corporation designing targeted blend therapies, delivered new positive data on progression-free survival (PFS) from the pivotal Phase III open-label TIGeR-PaC investigation of RenovoGem (intra-arterial administration of gemcitabine) in locally advanced pancreatic cancer (LAPC).

High Therapy Costs

The high cost of pancreatic cancer therapy is estimated to hamper the global locally advanced pancreatic cancer market growth in the forecast period. For instance, according to the American Society of Clinical Oncology, a six-month course of chemotherapy (Gemcitabine) expends about US$ 23,500. With the mixture of the drug Erlotinib, the therapy expenses are around USD 40,000.

Pancreatic cancer therapy is a highly priced therapy, for individuals without health coverage, pancreatic cancer therapy generally costs approximately $50,000-$200,000 or above, based on the kind and span of therapy. Total episode costs for pancreatic cancer care ranged from $35,601 (FOLFOX) to $45,851 (liposomal irinotecan), but the cost elements vary by regimen followed. Similarly, according to NIH, the unadjusted intermediate expense for pancreatic resection and corresponding hospitalization was around $20,352.

Therapy Side-effects

The side effects of chemotherapy rely on which medications are administered. Also, not all individuals have identical side effects even if the same medication is given. Overall the side effects include poor hunger, nauseousness, vomiting, diarrhea, gastrointestinal issues, hives, mouth sores, hair loss, and a deficiency of energy. Individuals accepting chemotherapy are even additional prone to hold low levels of WBCs, RBCs, and Thrombocytes, which puts the individuals at an increased threat of anemia, infections, bruising, and bleeding.

A few drugs utilized in pancreatic cancer are even connected with typical side effects. For instance, capecitabine can provoke redness and discomfort on the palms of the hands and the soles of the feet. This state is called hand-foot syndrome. Oxaliplatin can induce cold sensitivity numbness and tingling in the fingers and toes, anointed peripheral neuropathy. Peripheral neuropathy is an unwanted effect of nab-paclitaxel as well.

Segment Analysis

The global locally advanced pancreatic cancer market is segmented based on therapy, route of administration, end-user and region.

Chemotherapy is Expected to Dominate Market

Chemotherapy is estimated to hold a major share of the global locally advanced pancreatic cancer market which is around 38.6% of the market share as the initial treatment for locally advanced pancreatic cancer is systemic chemotherapy. The introduction of FOLFIRINOX chemotherapy and gemcitabine-nab-paclitaxel (gem-nab) holds significant importance for the management and results of patients with locally advanced pancreatic cancer.

For instance, according to a clinical investigation post 4-6 months of induction chemotherapy, the bulk of individuals showed steady condition or even tumor-regression. Around 12 to 35% of individuals successfully downstaged to resectable condition. Further, according to the first interim analysis of the phase III TIGeR-PaC trial presented at ESMO GI 2023, in individuals with locally advanced pancreatic cancer, therapy with intra-arterial gemcitabine directs to better survival and safety results than with the standard-of-care therapy with intravenous gemcitabine/nab-paclitaxel.

Geographical Penetration

Increasing Number of Pancreas Cancer Cases in North America

North America is estimated to hold around 38.2% of the total market share in 2023. Owing to the increasing number of pancreas cancer cases, government funding, and awareness initiatives are boosting the regional market growth during the forecast period. For instance, the American Cancer Society's Cancer Facts & Figures 2023, indicates that an assessed over 64,050 Americans to be detected with pancreatic cancer in 2023, more individuals than ever in history. Also, approximately 50,550 Americans are expected to die from the condition in 2023.

Further, pancreatic cancer is presently the 10th most highly detected cancer in the U.S., it remains the third-leading reason for cancer-related deaths. Pancreatic cancer is on the path to evolve as the second-highest reason for cancer-related mortalities before 2030. Similarly, according to the CDC Annual Report to the Nation 2022, in males, the most significant incidence rate boost was witnessed in pancreatic cancer, which grew by 1.1% per year, and the abruptest incidence rate reduction was witnessed in lung cancer, which fell by 2.6% per year. Furthermore, in August 2022, PanTher Therapeutics, a clinical-stage oncology corporation designing next-generation targeted treatments for solid tumors, acquired $14.2 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT).

The grant is intended to be employed to extend clinical development via Phase 2 of PanTher's principal investigational treatment, PTM-101, a minimally invasive, implantable therapy for non-metastatic pancreatic cancer that delivers a direct, sustained discharge of a known therapeutic drug at the tumor location. Additionally, in June 2023, a $3.3 million grant from the National Cancer Institute by the U.S. Department of Health and Human Services was awarded to UTHealth Houston to investigate a combination strategy of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with chemotherapy for pancreatic cancer.

Russia-Ukraine War Impact

The Russia-Ukraine conflict has negatively impacted the global locally advanced pancreatic cancer market growth. Since the invasion of Ukraine in February 2022, the execution of clinical trials has become quite difficult owing to the deterioration of healthcare establishments and patient displacement. For instance, according to an illustrative investigation, and narrative examination was conducted utilizing data from cancer clinical trials with sites in Russia or Ukraine employing the 'clinical trials.gov' online database between February 2022 and May 2022.

There were 508 clinical trials concerning locations in Ukraine or Russia. A majority of these were global investigations accounting for 93% of total studies. The most of investigations were phase 3 accounting for 68% of the total and these even held the most extensive specimen sizes ranging from 12-5637. This has created disruption in the treatment research activities hampering the growth in the forthcoming years.

COVID-19 Impact Analysis

The pandemic had an intermediate impact on the global market as at the beginning many procedures and visits were postponed or canceled which negatively impacted the market. However, according to the Pancreatic Cancer Organization UK, several individuals with pancreatic cancer are at elevated threat of becoming extremely ill if exposed to coronavirus infection. Individuals with people with cancer who are having chemotherapy have compromised immunity since the chemotherapy weakens the immune system, making it harder for the body to resist an infection.

Also, individuals who have had their spleen extracted, as some surgery for pancreatic cancer concerns removing the spleen are at increased threat for infection since the spleen is an important part of the immune system. Similarly, the individuals undergoing radiotherapy or immunotherapy may also be at elevated risk. This has caused immediate actions to restore the pancreatic cancer healthcare assistance programs.

By Therapy

  • Chemotherapy
    • Gemcitabine
    • 5-fluorouracil (5-FU)
    • Oxaliplatin
    • Albumin-bound paclitaxel (Abraxane)
    • Capecitabine (an oral 5-FU drug)
    • Cisplatin
    • Irinotecan
    • Others
  • Immunotherapy
    • Dostarlimab
    • Pembrolizumab
  • Targeted Therapy
    • Larotrectinib
    • Entrectinib
  • Radiation Therapy
  • Surgery
    • Whipple Procedure
    • Total Pancreatectomy
    • Distal Pancreatectomy

By Route of Administration

  • Oral
  • Injectables
  • Others

By End-User

  • Hospital
  • Specialty Clinics
  • Research Institutions
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In January 2022, Novartis AG obtained an Orphan Drug Designation (ODD) for NIS793 from the U.S. FDA. It integrates with other chemotherapy medications for the treatment of pancreatic cancer and other tumors.
  • In January 2022, AstraZeneca teamed with Scorpion Therapeutics to discover, design, and market precision therapies against formerly hard-to-target cancer proteins.
  • In September 2021 F. Hoffmann-La Roche Ltd collaborated with NovoCure to design Tumor Treating Fields (TTFields) in a mixture with anti-PD-L1 therapy, atezolizumab, for individuals detected with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Competitive Landscape

The major global players in the market include: Theratechnologies Inc., Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, AbbVie, Galderma Laboratories, L.P. and GlaxoSmithKline among others.

Why Purchase the Report?

  • To visualize the global locally advanced pancreatic cancer market segmentation based on therapy, route of administration, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of locally advanced pancreatic cancer market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The global locally advanced pancreatic cancer market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Cases of Locally Advanced Pancreatic Cancer
      • 4.1.1.2. Increasing Research Developments
    • 4.1.2. Restraints
      • 4.1.2.1. High Therapy Costs
      • 4.1.2.2. Therapy Side-effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Pipeline Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Patent Analysis
  • 5.7. End-User Trend
  • 5.8. SWOT Analysis
  • 5.9. DMI Opinion
  • 5.10. Russia-Ukraine War Impact

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 7.1.2. Market Attractiveness Index, By Therapy
  • 7.2. Chemotherapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Gemcitabine
    • 7.2.4. 5-fluorouracil (5-FU)
    • 7.2.5. Oxaliplatin
    • 7.2.6. Albumin-bound paclitaxel (Abraxane)
    • 7.2.7. Capecitabine (an oral 5-FU drug)
    • 7.2.8. Cisplatin
    • 7.2.9. Irinotecan
    • 7.2.10. Others
  • 7.3. Immunotherapy
    • 7.3.1. Dostarlimab
    • 7.3.2. Pembrolizumab
  • 7.4. Targeted Therapy
    • 7.4.1. Larotrectinib
    • 7.4.2. Entrectinib
  • 7.5. Radiation Therapy
  • 7.6. Surgery
    • 7.6.1. Whipple Procedure
    • 7.6.2. Total Pancreatectomy
    • 7.6.3. Distal Pancreatectomy

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Injectables
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Research Institutions
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GSK*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Merck & Co., Inc.
  • 12.3. Bristol-Myers Squibb Company
  • 12.4. Getwell
  • 12.5. Ipsen Biopharmaceuticals, Inc.
  • 12.6. Novartis Pharmaceuticals Corporation
  • 12.7. Pfizer
  • 12.8. Bayer HealthCare Pharmaceuticals, Inc.
  • 12.9. Genentech USA, Inc.
  • 12.10. AstraZeneca

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us